Q-omics provides the consensus-scored SNHG17 profile across patient tissues and cancer cell-line models. SNHG17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNHG17 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SNHG17 RNA expression shows 16,956 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where SNHG17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG17 survival associations across molecular data types. SNHG17 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG17 RNA expression–survival associations across cancer types. High SNHG17 expression shows unfavorable associations in KIRC, ACC, LIHC, KIRP, SARC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNHG17 RNA expression.
This table summarizes SNHG17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG17 shows higher tumor expression in COAD, KIRC, STAD, HNSC, LIHC and LUAD. The COAD box plot shows higher SNHG17 RNA expression in tumor versus normal tissue (log2 FC = +2.220, t-test p < 0.001).
This table shows molecular features associated with SNHG17 in patient tissues and cancer cell lines. In patient samples, SNHG17 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNHG17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
